VTYX Stock Price, Ventyx Biosciences, Inc. Quote, Chart

Market Summary

USD4.73-0.25

Delayed

-5.02%

VTYX Stock Price

View Fullscreen

VTYX RSI Chart

VTYX Valuation

Market Cap

333.5M

Price/Earnings (Trailing)

-1.73

Price/Free Cashflow

-1.81

VTYX Price/Earnings (Trailing)

VTYX Profitability

Return on Equity

-62.74%

Return on Assets

-58%

Free Cashflow Yield

-55.14%

VTYX Fundamentals

VTYX Earnings

Earnings (TTM)

-192.6M

Earnings Growth (Yr)

0.92%

Earnings Growth (Qtr)

17.5%

Breaking Down VTYX Revenue

Last 7 days

15.7%

Last 30 days

8.0%

Last 90 days

92.3%

Trailing 12 Months

-85.9%

How does VTYX drawdown profile look like?

VTYX Financial Health

Current Ratio

22

VTYX Investor Care

Shares Dilution (1Y)

20.39%

Diluted EPS (TTM)

-3.24

Tracking the Latest Insider Buys and Sells of Ventyx Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2024	nsv partners iii lp	sold	-	-	-695,339	-
Apr 12, 2024	subramaniam somu	sold	-	-	-695,339	-
Apr 02, 2024	nuss john	sold	-8,921	5.4034	-1,651	chief scientific officer
Apr 02, 2024	auster martin	sold	-7,591	5.4035	-1,405	chief financial officer
Apr 02, 2024	krueger christopher w	sold	-8,921	5.4036	-1,651	chief business officer
Apr 02, 2024	mohan raju	sold	-23,299	5.4034	-4,312	ceo and president
Mar 28, 2024	mohan raju	acquired	-	-	11,843	ceo and president
Mar 28, 2024	auster martin	acquired	-	-	4,531	chief financial officer
Mar 28, 2024	krueger christopher w	acquired	-	-	4,531	chief business officer
Mar 28, 2024	nuss john	acquired	-	-	4,531	chief scientific officer

Which funds bought or sold VTYX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-90.00	-90,360	25,883	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-73.69	-472,719	668,789	-%
May 15, 2024	Graham Capital Management, L.P.	sold off	-100	-1,143,900	-	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	new	-	737,000	737,000	0.05%
May 15, 2024	J. Goldman & Co LP	new	-	342,441	342,441	0.01%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	added	33.57	136,540	205,700	0.01%
May 15, 2024	Voya Investment Management LLC	added	486	564,619	611,430	-%
May 15, 2024	Redmile Group, LLC	added	944	11,390,900	11,902,700	0.44%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	added	110	5,475,780	6,957,780	0.01%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-75.57	-2,178,670	2,599,660	-%

Are Funds Buying or Selling VTYX?

Are funds buying VTYX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VTYX

No. of Funds

Unveiling Ventyx Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 04, 2024	flynn james e	5.03%	3,542,000	SC 13G
Mar 21, 2024	cormorant asset management, lp	5.21%	3,670,000	SC 13G
Mar 13, 2024	nsv investments i, l.p.	7.1%	5,004,071	SC 13D/A
Mar 08, 2024	nsv investments i, l.p.	8.5%	5,004,071	SC 13D/A
Feb 23, 2024	point72 asset management, l.p.	5.0%	2,977,868	SC 13G
Feb 14, 2024	citadel advisors llc	5.9%	6	SC 13G/A
Feb 13, 2024	vanguard group inc	6.34%	3,741,925	SC 13G
Jan 29, 2024	blackrock inc.	6.5%	3,814,531	SC 13G
Jan 29, 2024	tang capital partners lp	5.2%	3,100,000	SC 13G
Dec 11, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Ventyx Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	3	Insider Trading
May 17, 2024	4	Insider Trading
May 16, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 01, 2024	424B3	Prospectus Filed
Apr 29, 2024	EFFECT	EFFECT
Apr 26, 2024	EFFECT	EFFECT
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Ventyx Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Ventyx Biosciences, Inc. News

Latest updates

Ventyx Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	19.6%	332	278	322	349	389	371	420	262	278	291	149	-
Current Assets	21.0%	320	264	308	347	387	331	418	252	258	263	146	0.00
Cash Equivalents	175.1%	142	52.00	57.00	52.00	64.00	65.00	263	45.00	42.00	71.00	69.00	0.00
Net PPE	8.7%	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Liabilities	-25.7%	25.00	34.00	38.00	21.00	18.00	18.00	37.00	19.00	19.00	12.00	12.00	31.00
Current Liabilities	-34.7%	15.00	22.00	26.00	20.00	17.00	16.00	36.00	18.00	18.00	12.00	12.00	1.00
Shareholder's Equity	25.9%	307	244	284	328	372	354	384	243	259	279	-	-
Retained Earnings	-9.2%	-457	-419	-372	-318	-265	-226	-191	-160	-140	-117	-100	-32.50
Additional Paid-In Capital	15.3%	765	663	657	647	637	581	576	405	401	397	12.00	2.00
Shares Outstanding	19.0%	70.00	59.00	59.00	59.00	58.00	57.00	52.00	51.00	51.00	50.00	3.00	2.00
Float	-	-	-	-	1,300	-	-	-	385	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	7.8%	-47,625	-51,655	-34,664	-49,282	-30,921	-47,264	-23,989	-14,792	-12,726	-14,687	-11,041	-9,903	-3,019	-	-
Share Based Compensation	6.5%	6,543	6,145	8,008	7,868	6,567	4,828	4,167	4,131	3,444	1,393	969	288	80.00	-	-
Cashflow From Investing	-9.5%	41,765	46,125	38,891	34,819	-18,895	-140,840	64,162	18,250	-16,503	-143,090	-73,163	-11.00	1,899	-	-
Cashflow From Financing	16341.7%	96,184	585	1,625	2,473	48,646	-10,355	177,792	249	86.00	159,582	50,379	56,725	56,865	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VTYX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development (includes related party amounts of $254 and $250, respectively)	$ 33,747	$ 35,437
General and administrative	8,021	7,115
Total operating expenses	41,768	42,552
Loss from operations	(41,768)	(42,552)
Other (income) expense:
Interest income	(3,227)	(3,622)
Other expense	31	1
Total other (income) expense	(3,196)	(3,621)
Net loss	(38,572)	(38,931)
Unrealized gain (loss) on marketable securities	(62)	539
Foreign currency translation	(9)	23
Comprehensive loss	$ (38,643)	$ (38,369)
Net loss per share, basic	$ (0.62)	$ (0.68)
Net loss per share, diluted	$ (0.62)	$ (0.68)
Weighted average common shares outstanding, basic	61,829,976	57,638,923
Weighted average common shares outstanding, diluted	61,829,976	57,638,923

VTYX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 141,898	$ 51,579
Marketable securities	160,684	200,641
Prepaid expenses and other assets	17,177	12,125
Total current assets:	319,759	264,345
Property and equipment, net	828	762
Operating lease right-of-use assets	10,414	11,509
Restricted cash	975	975
Other long-term assets	102	102
Total assets	332,078	277,693
Current liabilities
Accounts payable	5,583	5,756
Accrued expenses	8,005	15,508
Current portion of operating lease liabilities	946	1,001
Total current liabilities	14,534	22,265
Operating lease liabilities, net of current portion	10,548	11,505
Total liabilities	25,082	33,770
Commitments and contingencies (Note 5)
Stockholders' equity:
Common stock, $0.0001 par value; 900,000,000 shares authorized at March 31, 2024 and December 31, 2023; 70,499,201 and 59,252,349 shares issued at March 31, 2024 and December 31, 2023, respectively; 70,493,906 and 59,239,113 shares outstanding at March 31, 2024 and December 31, 2023, respectively	7	6
Additional paid-in capital	764,869	663,154
Accumulated other comprehensive loss	(121)	(50)
Accumulated deficit	(457,759)	(419,187)
Total stockholders' equity	306,996	243,923
Total liabilities and stockholders' equity	$ 332,078	$ 277,693

About Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

CEO	Dr. Raju S. Mohan Ph.D.
WEBSITE	https://ventyxbio.com
INDUSTRY	Biotechnology
EMPLOYEES	91

Ventyx Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Ventyx Biosciences, Inc.? What does VTYX stand for in stocks?

VTYX is the stock ticker symbol of Ventyx Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ventyx Biosciences, Inc. (VTYX)?

As of Fri May 17 2024, market cap of Ventyx Biosciences, Inc. is 333.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTYX stock?

You can check VTYX's fair value in chart for subscribers.

What is the fair value of VTYX stock?

You can check VTYX's fair value in chart for subscribers. The fair value of Ventyx Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ventyx Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VTYX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ventyx Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether VTYX is over valued or under valued. Whether Ventyx Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Ventyx Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTYX.